Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

44.10 +2.99 (+7.27%)
Streaming Delayed Price Updated: 1:02 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Moderna, Inc. Shareholders - Robbins LLP Reminds MRNA Stockholders of the Class Action Lawsuit Against the Company – Seek Counsel Today
From Robbins LLP
Via GlobeNewswire
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Wellness In Your Personal Life Unleashes Productivity At Work
Our world is obsessed with individual productivity. 
Via Investor's Business Daily
Moderna Unusual Options Activity
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Is It Time to Buy August's Worst-Performing S&P 500 Stocks?
What happened to August's worst-performing stocks? Discover if these underperformers from the famous S&P 500 index are potential buys or value traps. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
Via Benzinga
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
Via Benzinga
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action
From Robbins LLP
Via GlobeNewswire
This Moderna Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185. 
Via Benzinga
INVESTOR ALERT:   Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
Exposures COVID-19
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
8 large-cap stocks were the worst performers last week: TBN, GFI, SNOW, NTES, BEN, JD, PDD, MRNA. Are they in your portfolio? 
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Kellanova and Fortinet are leading the S&P 500's August performance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
Moderna secures European Commission approval for its mRNA RSV vaccine, mRESVIA, to protect adults 60+ from RSV-related respiratory disease. The approval follows positive EMA CHMP opinion, based on... 
Via Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.